Evidence map›Paper›PMID 32454634›Full record

ArticleTurkish journal of pharmaceutical sciences2018

Preparation and

Nagaraju Ravouru, Subhash Chandra Bose Penjuri, Saritha Damineni, Raja Lakshmi Muni, Srikanth Reddy Poreddy

Abstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nagaraju RavouruSri Padmavati Mahila Visvavidyalayam, (Women's University), Institute of Pharmaceutical Technology, Tirupati, Andhra Pradesh, India.ORCID https://orcid.org/0000-0001-8795-1527
Subhash Chandra Bose PenjuriMNR College of Pharmacy, Department of Pharmaceutics, Sangareddy, Telangana, India.ORCID https://orcid.org/0000-0002-9365-0701
Saritha DamineniSultan-ul-Uloom College of Pharmacy, Department of Pharmaceutics, Hyderabad, Telangana, India.ORCID https://orcid.org/0000-0001-5056-8989
Raja Lakshmi MuniSri Padmavati Mahila Visvavidyalayam, (Women's University), Institute of Pharmaceutical Technology, Tirupati, Andhra Pradesh, India.
Srikanth Reddy PoreddyMNR College of Pharmacy, Department of Pharmaceutics, Sangareddy, Telangana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIbuprofen, an anti-inflammatory drug, is characterized by poor water solubility, which limits its pharmacologic effects. The present work aimed to the study the effect of agglomeration on the micromeritic properties and dissolution of ibuprofen. MATERIALS AND

methodsIbuprofen agglomerates were prepared by solvent change method using water, dichloromethane and DMSO as poor solvent, bridging liquid and good solvent respectively in the ratio of 57.5:12.5:30. Process variables such as amount of bridging liquid, mode of addition, temperature and stirring rate were optimized.

resultsSEM studies indicate that agglomerates produced were spherical and exhibit irregular shape. X-Ray Powder Diffraction spectra revealed the absence of polymorphism. DSC spectra showed no change in melting point indicating absence of crystal modification. The agglomerates exhibited improved solubility, dissolution rate and micromeritic properties compared to pure drug.

conclusionAnti-inflammatory studies were conducted in Wistar strain male albino rats and ibuprofen agglomerates showed more significant activity than the pure drug which may be due to better absorption. Ulcerogenic potential study was carried out for pure ibuprofen and agglomerates. Better ulcerogenic potential was observed in ibuprofen agglomerates treated rats.

Indexed as

anti-inflammatory activityIbuprofenspherical agglomerationulcerogenic potential

Identifiers

PMID32454634
PMCPMC7227892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.